Back to News
Market Impact: 0.35
Milestone Pharma Announces Approval Of Etripamil Nasal Spray In China; Triggers Milestone Payment
Source: Nasdaq
Regulation & LegislationHealthcare & BiotechProduct LaunchesCompany Fundamentals
Milestone Pharmaceuticals said China’s NMPA approved etripamil nasal spray for treating paroxysmal supraventricular tachycardia (PSVT) in adults. The approval is described as the first regulatory authorization for e... (ongoing from article text), a meaningful milestone that supports commercialization prospects in the China market.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
MIST0.75
More News
- US House votes to end Iran war, 7 Republicans join in favour
- Exclusive-SK Hynix in talks with Intel about deal to make memory chips in the US for the first time, sources say
- Grab aims for 'next level' in financial services with purchase of buy-now pay-later platform Atome
- Babcock affirms full-year guidance on strong defence, nuclear demand
- China's AI leaders keep quiet despite U.S. 'publicity' on tech risks
- America has lost 200 malls since 2008. Now the survivors are becoming Gen Z hangouts